(Q40877968)

24 September 2017

1 reference

title

Cardioprotection with angiotensin-converting enzyme inhibitors: redefined for the 1990s (English)

1 reference

24 September 2017

Kloner RA

1

1 reference

24 September 2017

Przyklenk K

series ordinal

2

1 reference

24 September 2017

publication date

1 February 1993

1 reference

24 September 2017

1 reference

24 September 2017

volume

16

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

95-103

1 reference

Clinical implications for therapy: possible cardioprotective effects of ACE inhibition

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Cardioprotective effects of captopril in myocardial ischaemia, ischaemia/reperfusion and infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

The stunned myocardium: prolonged, postischemic ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Postischemic myocardial "stunning": a clinically relevant phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Captopril: a free radical scavenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Role of collagen in acute myocardial infarct expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Influence of chronic captopril therapy on the infarcted left ventricle of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

ACE inhibitors in acute and chronic ischaemia: current status and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Prevention of nitrate tolerance with angiotension converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Focus on diastolic dysfunction: a new approach to heart failure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

Interactions between coronary occlusion and the renin-angiotensin system in the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Functional infarct expansion, left ventricular dilation and isovolumic relaxation time after coronary occlusion: a two-dimensional echocardiographic study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium").

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Captopril and enalaprilat do not scavenge the superoxide anion

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Sulfhydryl Group in Angiotensin Converting Enzyme Inhibitors and Superoxide Radical Formation

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Acute effects of hydralazine and enalapril on contractile function of postischemic "stunned" myocardium

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Increased survival in rats with congestive heart failure treated with enalapril

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

ACE Inhibition with Cilazapril Improves Myocardial Perfusion to the Ischemic Regions During Exercise

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Progress in cardioprotection: the role of calcium antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Angiotensin converting enzyme inhibitors. II. Clinical use.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Effects of captopril on survival in patients with heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

ACE inhibitors--a cornerstone of the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960160204

7 January 2021

Identifiers

DOI

10.1002/CLC.4960160204

1 reference

24 September 2017

1 reference